This video discusses the mechanism of action of cancer therapies - cell cycle inhibitors - CDK4/6 inhibitors.
#science #cancer #medicine

More videos coming soon. Please rate☝️, comment👇, and subscribe☝️ if you like them, so that I can make more! Please send through requests for topics to cover as well. What do you want to learn about? #scienceinmotion

Social
Check out other socials: TikTok - [ Ссылка ]
Instagram - [ Ссылка ]
Twitter - [ Ссылка ]
Facebook - [ Ссылка ]
Website - [ Ссылка ]

Music & images
Music thanks to: Vyond
Some images thanks to: Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License.
Some images designed by Freepik/vectorpouch/pch.vector/vectorpocket . Available from: www.freepik.com Some images adapted from
BioRender. Created with BioRender.com. Available from: [ Ссылка ]
Some images designed by Pixabay, licensed under Creative Commons Attribution 3.0 Unported License. Available from: [ Ссылка ]
Some images purchased from Shutterstock. Available from: [ Ссылка ] Some footage/images purchased from
Storyblocks. Available from: [ Ссылка ]

References
Howell A. Fulvestrant. In: Schwab M, editor. Encyclopedia of Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg; 2009. p. 1168-71.
Imamura Y, Sadar M. Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic2016.
Suzuki H, Ueda T, Ichikawa T, Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 2003;10(2):209-16.
Yamaoka M, Hara T, Kusaka M. Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer. Clinical Cancer Research. 2010;16(17):4319.
Drudge-Coates L. GnRH blockers: A changing paradigm in the management of prostate cancer2010. 85-92
Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nature Reviews Cancer. 2015;15:26
Brodie A, Sabnis G. Adaptive Changes Result in Activation of Alternate Signaling Pathways and Acquisition of Resistance to Aromatase Inhibitors. Clinical Cancer Research. 2011;17(13):4208.1.
Pietras RJ, Márquez-Garbán DC. Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers. Clinical Cancer Research. 2007;13(16):4672.
Makridakis N, Buchanan G, Tilley W, Reichardt J. Androgen metabolic genes in prostate cancer predisposition and progression2005. 2892-903 p.
Tripathy D, Bardia A, Sellers WR. Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. Clinical Cancer Research. 2017;23(13):3251.
Xu H, Yu S, Liu Q, Yuan X, Mani S, Pestell RG, et al. Recent advances of highly selective CDK4/6 inhibitors in breast cancer. Journal of Hematology & Oncology. 2017;10(1):97.
Ciruelos E, Pascual T, Arroyo Vozmediano ML, Blanco M, Manso L, Parrilla L, et al. The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer. The Breast. 2014;23(3):201-8.
Nathan MR, Schmid P. A Review of Fulvestrant in Breast Cancer. Oncology and Therapy. 2017;5(1):17-29.
cancer,oncology,mechanism of action,signalling,signaling,therapy,therapeutic,cell,breast cancer,estrogen,oestrogen,selective estrogen receptor modulator,receptor,DNA,nucleus,cell cycle

свернуть